Kamil Taneja

Dr. Kamil Taneja


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
MDMichael Diaz
Michael Diaz
NNNicole Natarelli
Nicole Natarelli
SAShaliz Aflatooni
Shaliz Aflatooni
SASarah Jane Aleman
Sarah Jane Aleman
SNSphurti Neelam
Sphurti Neelam
MFMahtab Forouzandeh
Mahtab Forouzandeh
Nanoparticles have shown marked promise as both antineoplastic agents and drug carriers. Despite strides made in immunomodulation, low success rates and toxicity remain limitations within the clinical oncology setting. In the present review, we assess advances in drug delivery nanoparticles, for systemic and topical use, in skin cancer treatment. A systematic review of controlled trials, meta-analyses, and Cochrane review articles was conducted. Eligibility criteria included: (1) a primary focus on nanoparticle utility for skin cancer; (2) available metrics on prevention and treatment outcomes; (3) detailed subject population; (4) English language; (5) archived as full-text journal articles. A total of 43 articles were selected for review. Qualitative analysis revealed that nanoscale systems demonstrate significant antineoplastic and anti-metastasis properties: increased drug bioavailability, reduced toxicity, enhanced permeability and retention effect, as well as tumor growth inhibition, among others. Nanoformulations for skin cancers have largely lagged behind those tested in other cancers–several of which have commercialized formulae. However, emerging evidence has indicated a powerful role for these carriers in targeting primary and metastatic skin cancers.

27 July 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
JTJasmine Thuy Tran
Jasmine Thuy Tran
MDMichael Diaz
Michael Diaz
DRDaphnee Rodriguez
Daphnee Rodriguez
GKGiona Kleinberg
Giona Kleinberg
SAShaliz Aflatooni
Shaliz Aflatooni
MFMahtab Forouzandeh
Mahtab Forouzandeh
Skin conditions are a significant cause of fatal and nonfatal disease burdens globally, ranging from mild irritations to debilitating diseases. Oxidative stress, which is an imbalance between reactive oxygen species and the cells’ ability to repair damage, is implicated in various skin diseases. Antioxidants have been studied for their potential benefits in dermatologic health, but the evidence is limited and conflicting. Herein, we conducted a systematic review of controlled trials, meta-analyses, and Cochrane review articles to evaluate the current evidence on the utility of antioxidant supplementation for adjunct prevention and treatment of skin disease and to provide a comprehensive assessment of their role in promoting dermatologic health. The Cochrane Library, PubMed, EMBASE, and Epistemonikos databases were queried. Eligibility criteria included (1) primary focus on nanoparticle utility for skin cancer; (2) includes measurable outcomes data with robust comparators; (3) includes a number of human subjects or cell-line types, where applicable; (4) English language; and (5) archived as full-text journal articles. A total of 55 articles met the eligibility criteria for the present review. Qualitative analysis revealed that topical and oral antioxidant supplementation has demonstrated preliminary efficacy in reducing sunburns, depigmentation, and photoaging. Dietary exogenous antioxidants (namely vitamins A, C, and E) have shown chemopreventive effects against skin cancer. Antioxidant supplementation has also shown efficacy in treating non-cancer dermatoses, including rosacea, psoriasis, atopic dermatitis, and acne vulgaris. While further studies are needed to validate these findings on a larger scale, antioxidant supplementation holds promise for improving skin health and preventing skin diseases.

6 August 2023 in Life
Verified
Journal Article
Open access
PDF file
NNNicole Natarelli
Nicole Natarelli
ABAleena Boby
Aleena Boby
SAShaliz Aflatooni
Shaliz Aflatooni
JTJasmine Thuy Tran
Jasmine Thuy Tran
MDMichael Diaz
Michael Diaz
MFMahtab Forouzandeh
Mahtab Forouzandeh
Non-coding RNAs (ncRNAs) have a significant regulatory role in the pathogenesis of skin cancer, despite the fact that protein-coding genes have generally been the focus of research efforts in the field. We comment on the actions of long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) in the current review with an eye toward potential therapeutic treatments. LncRNAs are remarkably adaptable, acting as scaffolding, guides, or decoys to modify key signaling pathways (i.e., the Wnt/β-catenin pathway) and gene expression. As post-transcriptional gatekeepers, miRNAs control gene expression by attaching to messenger RNAs and causing their degradation or suppression during translation. Cell cycle regulation, cellular differentiation, and immunological responses are all affected by the dysregulation of miRNAs observed in skin cancer. NcRNAs also show promise as diagnostic biomarkers and prognostic indicators. Unraveling the complexity of the regulatory networks governed by ncRNAs in skin cancer offers unprecedented opportunities for groundbreaking targeted therapies, revolutionizing the landscape of dermatologic care.

1 August 2023 in Stroke
Verified
Journal Article
Closed access
KPKaran Patel
Karan Patel
KTKamil Taneja
Kamil Taneja
MOMatthew B. Obusan
Matthew B. Obusan
SYShadi Yaghi
Shadi Yaghi
Thanh N NguyenThanh N Nguyen
Thanh N Nguyen
JSJames E. Siegler
James E. Siegler
BACKGROUND: Thrombectomy for basilar artery occlusion (BAO) has proven efficacy in patients with moderate-to-severe deficits, but has unclear benefits for those with mild symptoms. METHODS: Using an observational cohort design, the US National Inpatient Sample (2018–2020) was queried for adult patients with basilar artery occlusion and National Institutes of Health Stroke Scale (NIHSS) <10 for patients treated with thrombectomy versus medical management. The primary outcome of routine discharge (to home or self-care) was evaluated using multivariable logistic regression and propensity score matching, adjusted for baseline characteristics, stroke severity, and treatment with thrombolysis. RESULTS: Of 17 019 with basilar artery occlusion, 5795 patients met the criteria for inclusion criteria for our study, and 880 (15.4%) were treated with endovascular thrombectomy. In the propensity score–matched cohort, 880 patients were treated with medical management and endovascular thrombectomy, respectively. In multivariable regression, endovascular thrombectomy was associated with both an increased odds of routine discharge (odds ratio, 1.95 [95% CI, 1.31–2.90]; P =0.001) and a decreased length of hospital stay (B, −0.74 [95% CI, −1.36 to −0.11]; P =0.02) compared with medical management. In the propensity score matched cohort, endovascular thrombectomy remained associated with greater odds of routine discharge (2.01 [95% CI, 1.21–3.34]; P =0.007) but no difference in length of hospital stay (B, −0.22 [95% CI, −0.90 to 0.46]; P =0.53). CONCLUSIONS: Routine discharge was more common in this representative US cohort of patients with basilar artery occlusion and National Institutes of Health Stroke Scale <10 who underwent thrombectomy compared to conventional medical management. These findings suggest thrombectomy may be associated with better functional outcomes despite lower National Institutes of Health Stroke Scale and should be validated in a clinical trial setting.

1 March 2024 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
BHBill Hum
Bill Hum
KTKamil Taneja
Kamil Taneja
SBSean Bunachita
Sean Bunachita
HAHadi Ashor
Hadi Ashor
JSJeeyong Shin
Jeeyong Shin
KPKaran Patel
Karan Patel

6 January 2023 in COVID
Verified
Journal Article
Open access
PDF file
SBSai Batchu
Sai Batchu
MDMichael Diaz
Michael Diaz
JTJasmine Thuy Tran
Jasmine Thuy Tran
AFAngela Fadil
Angela Fadil
KTKamil Taneja
Kamil Taneja
Brandon Lucke-WoldBrandon Lucke-Wold
Brandon Lucke-Wold
Introduction: SARS-CoV-2 is the newest beta coronavirus family member to demonstrate neuroinvasive capability in severe cases of infection. Despite much research activity in the SARS-CoV-2/COVID-19 space, the gene-level biology of this phenomenon remains poorly understood. In the present analysis, we leveraged spatial transcriptomics methodologies to examine relevant gene heterogeneity in tissue retrieved from the human prefrontal cortex. Methods: Expression profiles of genes with established relations to the SARS-CoV-2 neuroinvasion process were spatially resolved in dorsolateral prefrontal cortex tissue (N = 4). Spotplots were generated with mapping to six (6) previously defined gray matter layers. Results: Docking gene BSG, processing gene CTSB, and viral defense gene LY6E demonstrated similar spatial enrichment. Docking gene ACE2 and transmembrane series proteases involved in spike protein processing were lowly expressed across DLPFC samples. Numerous other findings were obtained. Conclusion: Efforts to spatially represent expression levels of key SARS-CoV-2 brain infiltration genes remain paltry to date. Understanding the sobering history of beta coronavirus neuroinvasion represents a weak point in viral research. Here we provide the first efforts to characterize a motley of such genes in the dorsolateral prefrontal cortex.